Search results
Results From The WOW.Com Content Network
Retatrutide. Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). [1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or ...
A four-week supply of 2.5-milligram (mg) vials is $399, and a four-week supply of 5-mg vials is $529, less than half the list price of other GLP-1 medicines for obesity, according to Eli Lilly.
Orforglipron. Orforglipron (LY-3502970) is an oral, non-peptide, small molecule glucagon-like peptide-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. [1][2] It is easier to produce than current peptide GLP-1 agonists and is expected to be cheaper. [3]
(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not ...
Lilly said the online platform for weight loss drugs is only intended for people who currently meet the criteria for a weight loss drug in the U.S.: People with a BMI of at least 30 or a BMI of at ...
Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes [10][13][14][15] and for weight loss. [11][16] Tirzepatide is administered via subcutaneous injections (under the skin). [10][13] It is sold under the brand names Mounjaro for diabetes treatment, [10] and Zepbound for weight loss. [11]
(Reuters) - The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.
An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...